My bookmarksSign up free
Source

2011/497/EU: Commission Implementing Decision of 9 August 2011 authorising the placing on the market of fermented black bean extract as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2011) 5645)

2011/497/EU: Commission Implementing Decision of 9 August 2011 authorising the placing on the market of fermented black bean extract as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2011) 5645)

Regulation (EC) No 258/97 · Decision · 4 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Fermented black bean extract as specified in the Annex may be placed on the market in the Union as a novel food ingredient in food supplements without prejudice to the specific provisions of Directive 2002/46/EC and Regulation (EC) No 1925/2006, with a maximum intake of 4,5 g per day.

Article 2

Open ↗

The designation of the authorised fermented black bean extract by this Decision on the labelling of the foodstuff containing it shall be ‘fermented black bean (Soya) extract’ or ‘fermented Soya extract’.

Article 3

Open ↗

This Decision is addressed to CBC Co. Ltd, 2-15-13, Tsukima, Chuo-ku, Tokyo 104-0052, JAPAN.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX SPECIFICATIONS OF FERMENTED BLACK BEAN EXTRACT Description: Fermented black bean extract (Touchi extract) is a fine light-brown protein-rich powder obtained by water extraction of small soybeans ( Glycine max ) fermented with Aspergillus oryzae. The extract contains an a-glucosidase inhibitor. Chemical characteristics of fermented black bean extract fat Not more than 1 % protein Not less than 55 % water Not more than 7 % ash Not more than 10 % carbohydrate Not less than 20 % a-glucosidase inhibitory activity IC50 min 0,025 mg/ml Soy isoflavone Not more than 0,3 g/100 g

Other acts of the same type
Council Decision (CFSP) 2022/2321 of 25 November 2022 in support of the South-Eastern and Eastern Europe Clearinghouse for the Control of Small Arms and Light Weapons (SEESAC) for the implementation of the Regional Roadmap on combating illicit arms trafficking in the Western Balkans and in support of disarmament and arms control activities in South-East and East EuropeCouncil Implementing Decision (EU) 2022/2331 of 25 November 2022 on the appointment of the Chair and a full-time member of the Single Resolution BoardCouncil Decision (EU) 2022/2384 of 25 November 2022 on the approval, on behalf of the European Union, of the modification of the Union’s Schedule of Specific Commitments under the General Agreement on Trade in Services (GATS) to incorporate Annex 1 to the Declaration on the Conclusion of Negotiations on Services Domestic RegulationCouncil Decision (EU) 2022/2391 of 25 November 2022 on the position to be taken on behalf of the European Union within the Council of Members of the International Olive Council, as regards the trade standard applying to olive oils and olive-pomace oilsCouncil Decision (EU) 2022/2489 of 25 November 2022 on the position to be taken on behalf of the European Union at the 42nd meeting of the Standing Committee of the Convention on the conservation of European wildlife and natural habitats (the ‘Bern Convention’)Commission Implementing Decision (EU) 2023/468 of 25 November 2022 amending Decision 2007/116/EC as regards the introduction of an additional reserved number beginning with 116 (notified under document C(2022) 8407)Commission Implementing Decision (EU) 2022/2325 of 24 November 2022 not approving 1,2-benzisothiazol-3(2H)-one (BIT) as an active substance for use in biocidal products of product-type 10 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Decision (EU) 2022/2326 of 24 November 2022 not approving epsilon-metofluthrin as an active substance for use in biocidal products of product-type 19 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Decision (EU) 2022/2327 of 24 November 2022 not approving chloramin B as an active substance for use in biocidal products of product-types 2, 3, 4 and 5 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Decision (EU) 2022/2570 of 24 November 2022 not approving silver nitrate as an active substance for use in biocidal products of product-type 7 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Decision (EU) 2022/2298 of 23 November 2022 postponing the expiry date of the approval of propiconazole for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Decision (EU) 2022/2306 of 23 November 2022 granting derogations to certain Member States with respect to the transmission of statistics pursuant to Regulation (EC) No 1338/2008 of the European Parliament and of the Council, as regards statistics on healthcare facilities, healthcare human resources and healthcare utilisation (notified under document C(2022) 8341) (Only the Czech, Dutch, English, French, German, Greek, Irish, Portuguese, Romanian, Spanish and Swedish texts are authentic) (Text with EEA relevance)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next